The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease;Levodopa/carbidopa intestinalis gél kezelés hatása az életmino{combining double acute accent}ségre

Ideggyogyaszati Szemle

Volumn 67, Issue 7-8, 2014, Pages 245-250

  Kovács, Norbert ^a,b   Aschermann, Zsuzsanna ^a   Ács, Péter ^a   Bosnyák, Edit ^a   Deli, Gabriella ^a   Janszky, József ^a,b   Komoly, Sámuel ^c  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c NONE

Author keywords

Parkinson's disease; Quality; Rating scales

Indexed keywords

CARBIDOPA PLUS LEVODOPA; ANTIPARKINSON AGENT; CARBIDOPA; GEL; LEVODOPA;

AGED; ARTICLE; CLINICAL ARTICLE; DAYTIME SOMNOLENCE; DEPRESSION; DISEASE DURATION; GEL; HUMAN; PARKINSON DISEASE; QUALITY OF LIFE; SLEEP QUALITY; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DRUG COMBINATION; FEMALE; HEALTH STATUS; INTESTINE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; ASSESSMENT OF HUMANS; BECK DEPRESSION INVENTORY; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE SEVERITY; DRUG EFFICACY; EPWORTH SLEEPINESS SCALE; EQ 5D 5L; HOEHN AND YAHR SCALE; MDS UPDRS; PDQ 39; PDSS 2; PREDICTIVE VALUE; RATING SCALE; SYMPTOM; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE;

ACTIVITIES OF DAILY LIVING; AGED; ANTIPARKINSON AGENTS; CARBIDOPA; DRUG THERAPY, COMBINATION; FEMALE; GELS; HEALTH STATUS; HUMANS; INTESTINES; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84906219931     PISSN: 00191442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Kovács N. A Parkinson-kór evidenciákon alapuló kezelése. Evidence-based treatment of Parkinson's disease. Orvostovábbképzo{combining double acute accent} Szemle 2011; 18(Különszám 2011 július):11-7.
2. Aschermann Z, Kovacs N, Komoly S. Folyamatos dopaminerg stimuláció Parkinson-kórban: leheto{combining double acute accent}ségek 2013-ban. Ideggyogy Sz 2013;66(5-6):209-10.
3. Kovács N, Balás I, Llumiguano C, Aschermann Z, Nagy F, Janszky J, et al. Mély agyi stimuláció: egy új perspektíva a mozgászavarok kezelésében. Lege Artis Medicinae 2009;19(2):119-26.
4. Klivenyi P, Vecsei L. Levodopa/carbidopa intestinalis géllel végzett klinikai vizsgálatok. Ideggyogy Sz 2014;67(1-2):5-8.
5. Fehér G, Balás I, Komoly S, Dóczi T, Janszky J, Aschermann Z, et al. A kétoldali szubtalamikus stimuláció hatékonysága az antiparkinson gyógyszerelés változtatásának tükrében. Ideggyogy Sz 2010;63(9-10):314-9.
6. Tamás G, Takáts A, Radics P, Rózsa I, Csibri É, Rudas G, et al. A mély agyi stimuláció hatékonysága Parkinsonkóros betegeink kezelé sében. Ideggyogy Sz 2013;66(3-4):115-20.
7. Takáts A, Nagy H, Radics P, Tóth A, Tamás G. Kezelési leheto{combining double acute accent}ségek a Parkinson-kór elo{combining double acute accent}rehaladott stádiumában. Ideggyogy Sz 2013;66(11-12):365-71.
8. Horváth K, Aschermann Z, Ács P, Bosnyák E, Deli G, Pál E, et al. Az MDS-UPDRS magyar validációja: Miért szükséges újabb Parkinson-pontozóskála? Ideggyogy Sz 2014;67(3-4):129-34.
9. Szende A, Nemeth R. Health-related quality of life of the Hungarian population. Orv Hetil 2003;144(34):1667-74.
10. Fazekas G, Kulmann L. Parkinsonos betegek életmino{combining double acute accent}ségét vizsgáló kérdo{combining double acute accent}ív (PDQ-39) magyarországi adaptációja. Ideggyogy Sz 2001;54(1-2):42-4.
11. Cheung YB, Tan LC, Lau PN, Au WL, Luo N. Mapping the eight-item Parkinson's Disease Questionnaire (PDQ-8) to the EQ-5D utility index. Qual Life Res 2008;17(9):1173-81.
12. Luo N, Low S, Lau PN, Au WL, Tan LC. Is EQ-5D a valid quality of life instrument in patients with Parkinson's disease? A study in Singapore. Ann Acad Med Singapore 2009;38(6):521-8.
13. Luo N, Ng WY, Lau PN, Au WL, Tan LC. Responsiveness of the EQ-5D and 8-item Parkinson's Disease Questionnaire (PDQ-8) in a 4-year follow-up study. Qual Life Res 2010;19(4):565-9.
14. Schrag A, Selai C, Jahanshahi M, Quinn NP. The EQ-5D - a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;69(1):67-73. (Pubitemid 30410417)
15. Klivenyi P, Vecsei L. The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life. Ideggyogy Sz 2008;61(1-2):42-8.
16. Bokor M, Szentesi A. The effect of Stalevo-dosing on quality of life of Parkinsonian patients with wearing-off. Ideggyogy Sz 2010;63(7-8):247-51.
17. Deli G, Balás I, Komoly S, Dóczx T, Janszky J, Illés Z, et al. Dystonia kezelése mély agyi stimuláció val: 40 eset tapasztalatainak összefoglalása. Ideggyogy Sz 2012;65(7-8):249-60.
18. Kovács N, Pál E, Janszky J, Bosnyák E, Ács P, Aschermann Z, et al. Parkinson's disease Sleep Scale-2 and Epworth Sleep Scale. J Neurol Sci 2013;333(Suppl 1):e139.
19. Goetz CG, Stebbins GT, Theeuwes A, Stocchi F, Ferreira JJ, van de Witte S, et al. Temporal stability of the Unified Dyskinesia Rating Scale. Mov Disord 2011;26(14):2556-9.
20. Goetz CG, Nutt JG, Stebbins GT. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord 2008;23(16):2398-403.
21. Foltynie T, Magee C, James C, Webster GJ, Lees AJ, Limousin P. Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series. Parkinsons Dis 2013;2013:362908.
22. Annic A, Devos D, Seguy D, Dujardin K, Destee A, Defebvre L. Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety. Rev Neurol (Paris) 2009; 165(8-9):718-27.
23. Lundqvist C, Nystedt T, Reiertsen O, Grotli R, Beiske AG. Continuous treatment with levodopa of Parkinson disease. Tidsskr Nor Laegeforen 2005;125(19):2638-40. (Pubitemid 41473324)
24. Santos-Garcia D, Macias M, Llaneza M, Fuster-Sanjurjo L, Echarri-Piudo A, Belmonte S, et al. Experience with continuous levodopa enteral infusion (Duodopa®) in patients with advanced Parkinson's disease in a secondary level hospital. Neurologia 2010;25(9):536-43.
25. Nyholm D. Duodopa® treatment for advanced Parkinson's disease: a review of efficacy and safety. Parkinsonism Relat Disord 2012;18(8):916-29.
26. Odin P, Wolters E, Antonini A. Continuous dopaminergic stimulation achieved by duodenal levodopa infusion. Neurol Sci 2008;29(Suppl 5):S387-8.
27. Fernandez HH, Vanagunas A, Odin P, Espay AJ, Hauser RA, Standaert DG, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. Parkinsonism Relat Disord 2013;19(3):339-45.
28. Hiroe T, Kojima M, Yamamoto I, Nojima S, Kinoshita Y, Hashimoto N, et al. Gradations of clinical severity and sensitivity to change assessed with the Beck Depression Inventory-II in Japanese patients with depression. Psychiatry Res 2005;135(3):229-35. (Pubitemid 40984614)